Panel-based assays that simultaneously screen for multiple streptococcal strains (for example, assays that detect Group A, B, C, and G or alpha/gamma-hemolytic species) are listed as not meeting coverage. The policy specifically names examples such as the Solana Strep Complete Assay and the Lyra Direct Strep Assay as non-covered panel tests that use immunoassay or nucleic acid–based methods. MALDI-TOF identification of streptococcal species is also listed as not meeting coverage, as is the quantification of streptococcal nucleic acid (NAAT/PCR) and certain enzymatic immunoassays (e.g., nicotinamide-adenine dinucleotide assays).

Although several named assays have FDA clearance or approval (for example, the Lyra Direct Strep Assay and the Solana Strep Complete Assay are described in the policy source), the coverage stance remains that multispecies screening panels and identification by MALDI-TOF or nucleic acid quantification are excluded due to insufficient published evidence of clinical benefit for the listed indications.

The document contains reference material and citations supporting diagnostic evaluation of streptococcal infections (peer-reviewed studies, FDA 510(k) summaries, and guideline sources). These reference-only sections do not themselves introduce additional explicit coverage exclusions beyond those enumerated elsewhere in the policy.

Rapid antigen detection tests (RADTs) for streptococcal infection are limited by the policy. RADT use is not covered as a follow-up test after a culture or NAAT, as a screening method in asymptomatic patients, or for individuals with suspected viral pharyngitis, except for an explicit narrow exception for asymptomatic children under age 3 years with a mitigating circumstance (such as a symptomatic household member). Ordering a bacterial throat culture for suspected viral pharyngitis is specifically stated to not meet coverage.

In operational terms, providers should avoid ordering RADT for screening of asymptomatic patients or to evaluate likely viral sore throat, and should not use RADT as a redundant follow-up to more definitive culture or molecular testing. Clinical documentation supporting indication (symptoms, Centor score, or other viral features) should accompany orders when testing is pursued for covered indications.

Some sections of the source document are reference-only and do not assert additional not-medically-necessary rulings. These chunks provide supporting literature, FDA summaries, and guideline citations but do not add separate exclusions or NMN statements to the policy content.

The policy lists multiple categories of tests and situations that do not meet coverage: panel assays that detect multiple streptococcal strains (e.g., Solana Strep Complete Assay, Lyra Direct Strep Assay), MALDI-TOF identification of streptococcus, and quantification of streptococcal nucleic acid by NAAT/PCR. Additionally, certain enzymatic immunoassays such as nicotinamide-adenine dinucleotide activity assays and broad serologic testing outside the defined indications are listed as not covered.

The policy also identifies procedural ordering denials that can result from duplicative testing practices: simultaneous ordering of both direct probe and amplification probe NAAT methods for the same organism in a single encounter does not meet coverage. These items are presented as not covered due to lack of published scientific literature demonstrating clinical benefit for the indicated purposes.

Reference-only portions of the policy include literature citations, FDA 510(k) summaries, and diagnostic performance studies that support the broader diagnostic context. These sections do not themselves enumerate additional non-covered tests or exclusions beyond the policy statements.

Streptococcus species cause a spectrum of disease from pharyngitis (commonly Group A Streptococcus, S. pyogenes) to skin and soft tissue infections, invasive disease, and post-infectious immune complications such as acute rheumatic fever (ARF) and post-streptococcal glomerulonephritis (PSGN). Diagnostic methods discussed in the policy include conventional culture, rapid antigen detection tests (RADT), and nucleic acid–based assays (NAAT/PCR); the document also references molecular and platform-specific FDA-cleared assays (for example, Lyra, Solana, GenePOC, Accula) and laboratory-developed tests regulated under CLIA.

The policy frames coverage around clinical context: throat culture is covered for suspected bacterial pharyngitis when clinical criteria such as a modified Centor score >= 3, absence of viral features, or a negative RADT in a symptomatic child/adolescent are present. Blood cultures are covered for patients who fail to improve, have progressive symptoms after antibiotics, or in suspected prosthetic joint infection. Serologic testing (titers and specific immunoassays) is covered when ordered for suspected ARF or PSGN; conversely, broad serologic testing and certain advanced identification or quantification methods are listed as not covered.